New technology has shown promise for detecting CTE and the approximately 150 protein biomarkers linked to conditions in neurology, oncology, cardiology, inflammation, and infectious disease. Called Simoa™, it is a single-molecule array on a fully automated digital immunoassay platform that detects…
In The News
Alzforum | November 17, 2017
Serum NfL levels rise before symptoms appear in familial AD. NfL correlates with cognitive decline and brain atrophy. In MS patients, NfL levels drop with treatment.
The Guardian| October 30, 2017
Several firms trying to develop new methods to assess extent of damage
Alzforum | September 21, 2017
In this month’s JAMA Neurology, two papers examine whether tau circulating in plasma could offer a blood-based biomarker for brain disorders.
CLP | July 11, 2017
Quanterix Corp, Lexington, Mass, has launched the Simoa Neurology 4-Plex A assay (N4PA).
Drug Discovery & Development News | July 11, 2017
Published jointly by Quanterix, DestiNA Genomics Ltd., Edinburgh University and the Pfizer-Universidad de Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENyO), the study, titled, “Polymerase-free measurement of microRNA-122 with single base specificity using single…
Neurology Advisor | June 6, 2017
Levels of neurofilament light chain (NfL) in cerebrospinal fluid (CSF) and plasma can help predict the rate of disease progression in patients with progressive supranuclear palsy (PSP). Results of the study were presented at the 2017 International Congress of Parkinson's Disease and Movement…
SportTechie| May 17, 2017
Simoa is considerably advancing the study of concussions because researchers are using it to detect biomarkers — proteins whose concentrations can be indicative of TBI — that were previously undetectable. The most well-known of these concussion biomarkers is a protein called tau.
May 5, 2017 | Cheddar
Cheddar, the live and on demand video news network focused on covering the most innovative products, technologies and services transforming our lives, recently interviewed Quanterix CEO and Executive Chairman Kevin Hrusovsky.
MedPage Today | March 28, 2017
Neurofilament light levels correlated with mental deficits but short on specificity